Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk

NCT01702207 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Immunosuppression
Cardiovascular Diseases
Kidney Transplantation

Interventions

DRUG: Once Daily Tacrolimus
DRUG: Twice Daily Tacrolimus

Sponsor

University of Saskatchewan

Collaborators

[object Object]